These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8170728)

  • 1. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants.
    Isacson J; Trollfors B; Taranger J; MacDowall I; Johansson J; Lagergård T; Robbins JB
    Pediatr Infect Dis J; 1994 Jan; 13(1):22-7. PubMed ID: 8170728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children.
    von Linstow ML; Pontoppidan PL; von König CH; Cherry JD; Hogh B
    Eur J Pediatr; 2010 Sep; 169(9):1119-22. PubMed ID: 20373111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children.
    Krantz I; Sekura R; Trollfors B; Taranger J; Zackrisson G; Lagergård T; Schneerson R; Robbins J
    J Pediatr; 1990 Apr; 116(4):539-43. PubMed ID: 2319400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis.
    Isacson J; Trollfors B; Taranger J; Lagergård T
    Pediatr Infect Dis J; 1995 Jun; 14(6):517-21. PubMed ID: 7667057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
    Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
    BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R; Lønnes T; Møgster B; Berdal BP
    Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy.
    Kent A; Ladhani SN; Andrews NJ; Matheson M; England A; Miller E; Heath PT;
    Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27255149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
    Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
    Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
    Taranger J; Trollfors B; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    J Infect Dis; 2000 Mar; 181(3):1010-3. PubMed ID: 10720524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
    Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
    Podda A; De Luca EC; Titone L; Casadei AM; Cascio A; Peppoloni S; Volpini G; Marsili I; Nencioni L; Rappuoli R
    J Pediatr; 1992 May; 120(5):680-5. PubMed ID: 1578301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiological situation of pertussis in the Federal Republic of Germany.
    Finger H; Wirsing von König CH; Tacken A; Wassilak SG
    Dev Biol Stand; 1991; 73():343-55. PubMed ID: 1778329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dot immunoassay for the simultaneous determination of postvaccination immunity against pertussis, diphtheria, and tetanus.
    Khramtsov P; Bochkova M; Timganova V; Zamorina S; Rayev M
    Anal Bioanal Chem; 2017 Jun; 409(15):3831-3842. PubMed ID: 28374129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
    Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
    APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.